Redefining high-risk prostate cancer based on distant metastases and mortality after high-dose radiotherapy with androgen deprivation therapy.
暂无分享,去创建一个
J. Ciezki | C. Reddy | E. Klein | P. Kupelian | A. Mahadevan | K. Stephans | R. Tendulkar
[1] A. Jemal,et al. Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.
[2] M. Cooperberg,et al. Minimal impact of clinical stage on prostate cancer prognosis among contemporary patients with clinically localized disease. , 2010, The Journal of urology.
[3] A. D'Amico,et al. Androgen‐Deprivation Therapy in Prostate Cancer and Cardiovascular Risk: A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology , 2010, CA: a cancer journal for clinicians.
[4] P. Scardino,et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Matthew R Cooperberg,et al. Time trends and local variation in primary treatment of localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Weichselbaum,et al. Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy. , 2009, International journal of radiation oncology, biology, physics.
[7] M. Piérart,et al. Duration of androgen suppression in the treatment of prostate cancer. , 2009, The New England journal of medicine.
[8] A. D'Amico,et al. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. , 2009, JAMA.
[9] A. Renshaw,et al. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials. , 2009, International journal of radiation oncology, biology, physics.
[10] M. Roach,et al. Predictive models in external beam radiotherapy for clinically localized prostate cancer , 2009, Cancer.
[11] J. Lebesque,et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. , 2008, International journal of radiation oncology, biology, physics.
[12] Yoshiya Yamada,et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. , 2008, International journal of radiation oncology, biology, physics.
[13] Yoshiya Yamada,et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. , 2008, International journal of radiation oncology, biology, physics.
[14] D. Grignon,et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Lei Dong,et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. , 2008, International journal of radiation oncology, biology, physics.
[16] Sylvie Chabaud,et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Charles R. Thomas,et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. , 2007, International journal of radiation oncology, biology, physics.
[18] M. Parmar,et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. , 2007, The Lancet. Oncology.
[19] Anthony D'Amico,et al. Prostate cancer. Clinical practice guidelines in oncology. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.
[20] A. D'Amico,et al. Cancer‐specific mortality after radiation therapy with short‐course hormonal therapy or radical prostatectomy in men with localized, intermediate‐risk to high‐risk prostate cancer , 2006, Cancer.
[21] Paul Schellhammer,et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.
[22] Daniel W. Miller,et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. , 2005, JAMA.
[23] James A Hanley,et al. Prostate cancer and the Will Rogers phenomenon. , 2005, Journal of the National Cancer Institute.
[24] A. Renshaw,et al. Adult urologyUrological survey: urological oncology: prostate cancerPretreatment PSA Velocity and Risk of Death From Prostate Cancer Following External Beam Radiation Therapy , 2006 .
[25] D. Grignon,et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. , 2005, International journal of radiation oncology, biology, physics.
[26] A. Renshaw,et al. Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] J. Manola,et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. , 2004, JAMA.
[28] Jacques Bernier,et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial , 2002, The Lancet.
[29] M W Kattan,et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] A. Renshaw,et al. Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer , 1998 .
[31] A R Feinstein,et al. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. , 1985, The New England journal of medicine.